MIAMI, May 05, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Organicell Flow, for patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection. [Read more…]
Caladrius Biosciences to Assess Cell Therapy (CLBS119) for COVID-19 Induced Lung Damage
FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure
BASKING RIDGE, N.J. (April 23, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the U.S. Food and Drug Administration (“FDA”) has authorized its investigational new drug (“IND”) application for the study of CLBS119, a CD34+ cell therapy for repair of COVID-19 induced lung damage. The study will target patients with severe SARS-CoV-2 infection that required ventilatory support due to respiratory failure. [Read more…]
Capricor Treats Two COVID-19 Patients with Cardiosphere-Derived Cells (CAP-1002)
Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy.
LOS ANGELES, April 03, 2020 — Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, announced it is providing CAP-1002, its novel cell therapy to patients with advanced COVID-19 under the compassionate use pathway. [Read more…]
NantKwest, ImmunityBio Advance BM-MSCs, NK Cell Therapies & Vaccines Against COVID-19
Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS).
- Therapeutic for Severe and Critically Ill COVID-19 Patients on Ventilator Support:
- NantKwest’s MSCs: Bone marrow-derived mesenchymal stem cells (MSC) to mitigate ‘cytopathic storm’ [Read more…]
Cure Alliance Launches 24-Patient Trial Using UC-MSCs Against COVID-19 Complications
FDA Authorizes Cure Alliance Rxperts to Test UC-MSCs
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- Next Page »